Self assembly Biological molecules are important lines to understand the molecular basis of complex metabolic events. The presence of cosolvent in aqueous solution during the self-assembly process can promote the formation of a metasable intermediary that is trapped in Kina. In nature, cosolvents categories called osmolytes can work to strengthen hydrogen bond tissue in such a way that the original conditions of certain proteins are preferred, thus modulating their functions and stability. However, identifying COSOLVENTs that act as osmolytes in biomimetic applications, such as self-assignment of soft materials, remain challenging.

This work examines the effects of ethanol (ETOH) and acetonitrile (ACN) as cosolven at the self-assignment of Amphiphilic Polypeptide PSAR30- (L-LEU-AIB) 6 (S30L12), which combines α-helical hydrophobic blocks, in aqueous solution. The result gives direct observation of the morphological behavior of S30L12 as a function of solvent composition. Morfological transitions are investigated using electron microscope transmissions, while peptide molecular packaging is assessed using circular blocked analysis and evaluating membrane fluidity.

In the mixture of Etoh / H2O, EtOH strengthens the water hydrogen bond tissue, thus limiting the hydrophobic hydration of the S30L12 assembly and increasing hydrophobic interactions between assemblies. Conversely, ACN forms its own nanoclusters in water and on the hydrophobic core of peptide assemblies to stabilize the edges exposed to bulk water and increase assembly kinetics. Fourier Transform Infrared Analysis (FT-IR) shows that EtOH and ACN can modify biomaterial self assembly in the same way as protective or denaturant osmolyte.

Poisonous polypeptide production as fusion inside the recit cavity

This system was developed for efficient biosynthetic production of painsty polypeptides. A polipeptide target produced blends into the T. thermophilus tassel polpeptide in such a way that it is served in the purai cavity near the substrate binding surface. Such presentations allow the relieve potential issues instability, toxicity or peptide hydrophobicity that blends. Thermostilical thermostabilities can be used to separate a one-step from the host cell protein by heating. The target of polypeptides can be released by special chemical care amino acids.

In this study, Groel was adapted for special methionine cleavage with cyanogen bromide with a total metionine residue replacement to facilitate further purification of the polipeptide target. The procedure is simple, strong, and easy to improve. The capacity of this system to produce polypeptides that is difficult to express is shown by production in the bacterial system from one of the most powerful antibacterial peptides polyphemusin I.

Adenilaty Adenilaty Polypeptide Adenilaty Cyclase: Neuroprotective Peptides that Promise in Stroke

Searching for effective and effective care for acute strokes continues to be a global priority due to high mortality and morbidity. Terapeutic treatment currently has limited effects, making searches for imperative new care. Polypeptides in the pituitary clasp (Pacip) are established cytoprotective neuropeptide participating in various physiological and pathological activities of nerves, such as neuron proliferation, differentiation, and migration, and neuroprotection. This is considered a promising treatment in many neurological diseases.

Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Here, we provide an overview that is related to the current PACAP knowledge, its receptors, and the potential role of neuroprotective in stroke settings, as well as various neuroprotecting mechanisms involving ion homeostasis, excitoxicity, cell edema, and oxidative stress ,, and cell death, and the route of giving Pacap.

Polypeptide Amyloid Islet & Beta Amyloid Peptide Role In Alzheimer’s Disease: Two Triggers, One Disease

Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions throughout the world. Because of the aging of the population, advertising events increase. Ad patients develop cognitive and dementia decreases, known features, requires permanent care. This raises the main socio-economic burden on the health care system because relatives and health workers are patients forced to overcome the increasing number of people affected. Despite the latest advances, the pathological mechanism of advertising is not fully understood.

However, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaque in the brain of AD patients, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of millions of people globally. The amyloid polypeptide (IAPP) islet is a hormone produced and released by insulin in the β-β pancreas, with a key role of diabetes, because it helps regulate glucose levels and control adiposity and pursuit. Likewise with Aβ, IAPP is very amyloidogenic, produces intracellular amyloid deposits that cause β cell dysfunction and death.

BCL3 Peptide
7183P	ProSci	0.05 mg	EUR 197.7
Description: (CT) BCL3 Peptide

BCL-10 Peptide
2161P	ProSci	0.05 mg	EUR 197.7
Description: (NT) BCL-10 peptide

Bcl-2 Peptide
3335P	ProSci	0.05 mg	EUR 197.7
Description: (NT) Bcl-2 peptide

Bcl-2 Peptide
3337P	ProSci	0.05 mg	EUR 197.7
Description: (IN) Bcl-2 peptide

Bcl9L Peptide
6213P	ProSci	0.05 mg	EUR 197.7
Description: (NT) Bcl9L peptide

BCL7A Peptide
45-325P	ProSci	0.1 mg	EUR 405.6
Description: BCL7A Peptide

BCL2A1 Peptide
42-665P	ProSci	0.1 mg	EUR 405.6
Description: (IN) BCL2A1 Peptide

BCL2L15 Peptide
43-245P	ProSci	0.1 mg	EUR 405.6

BCL2L15 Peptide
42-323P	ProSci	0.1 mg	EUR 405.6
Description: (IN) BCL2L15 Peptide

BCL10 Blocking Peptide
DF6246-BP	Affbiotech	1mg	EUR 234

BCL10 Blocking Peptide
DF3606-BP	Affbiotech	1mg	EUR 234

BCL11A Blocking Peptide
AF7561-BP	Affbiotech	1mg	EUR 234

BCL11A Blocking Peptide
33R-10043	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8372

BCL11A Blocking Peptide
33R-6490	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8336

BCL11A Blocking Peptide
DF7345-BP	Affbiotech	1mg	EUR 234

BCL11B Blocking Peptide
DF2464-BP	Affbiotech	1mg	EUR 234

BCL2 Blocking Peptide
20-abx062289	Abbexa	EUR 326.40 EUR 493.20	1 mg 5 mg

Bcl2 Blocking Peptide
33R-10602	Fitzgerald	50 ug	EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl2 antibody, catalog no. 70R-11571

BCL3 Blocking Peptide
33R-10746	Fitzgerald	50 ug	EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL3 antibody, catalog no. 70R-11804

BCL9 Blocking Peptide
DF12515-BP	Affbiotech	1mg	EUR 234

BCL2 Blocking Peptide
20-abx161300	Abbexa	EUR 326.40 EUR 493.20	1 mg 5 mg

BCL2 Blocking Peptide
20-abx161556	Abbexa	EUR 727.20 EUR 1713.60	1 mg 5 mg

BCL9L Blocking Peptide
AF7915-BP	Affbiotech	1mg	EUR 234

BCL7A Blocking Peptide
33R-1704	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3771

BCL6B Blocking Peptide
33R-5338	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL6B antibody, catalog no. 70R-8459

BCL7A Blocking Peptide
33R-7534	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3765

BCL6B Blocking Peptide
DF9075-BP	Affbiotech	1mg	EUR 234

BCL7A Blocking Peptide
DF4737-BP	Affbiotech	1mg	EUR 234

BCL7B Blocking Peptide
DF2586-BP	Affbiotech	1mg	EUR 234

BCL7C Blocking Peptide
DF2587-BP	Affbiotech	1mg	EUR 234

BCL2A1 Blocking Peptide
33R-2930	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2A1 antibody, catalog no. 70R-10524

BCL2L1 Blocking Peptide
33R-8657	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 20R-1065

BCL2L1 Blocking Peptide
33R-5547	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10444

BCL2L1 Blocking Peptide
33R-6481	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10443

BCL2A1 Blocking Peptide
DF7652-BP	Affbiotech	1mg	EUR 234

BCL2L1 Blocking Peptide
DF6015-BP	Affbiotech	1mg	EUR 234

BCL2L2 Blocking Peptide
DF6292-BP	Affbiotech	1mg	EUR 234

BCL2L13 Blocking Peptide
33R-9493	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L13 antibody, catalog no. 70R-10451

BCL2L12 Blocking Peptide
33R-4918	Fitzgerald	100 ug	EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L12 antibody, catalog no. 70R-10366

BCL2L14 Blocking Peptide
DF9220-BP	Affbiotech	1mg	EUR 234

BCL2L12 Blocking Peptide
DF3830-BP	Affbiotech	1mg	EUR 234

BCL2L13 Blocking Peptide
DF6248-BP	Affbiotech	1mg	EUR 234

BCL2L10 Blocking Peptide
DF2276-BP	Affbiotech	1mg	EUR 234

BCL2L13 Blocking Peptide
DF2649-BP	Affbiotech	1mg	EUR 234

BCL-3 Blocking Peptide
AF7756-BP	Affbiotech	1mg	EUR 234

Bcl-2 Blocking Peptide
3033BP-50	Biovision	each	EUR 183.6

Bcl-3 Blocking Peptide
3407BP-50	Biovision	each	EUR 183.6

Bcl-6 Blocking Peptide
3408BP-50	Biovision	each	EUR 183.6

Bcl-2 Blocking Peptide
BF9103-BP	Affbiotech	1mg	EUR 234

BCL-2 Blocking Peptide
AF0769-BP	Affbiotech	1mg	EUR 234

Bcl-2 Blocking Peptide
AF4700-BP	Affbiotech	1mg	EUR 234

BCL-2 Blocking Peptide
AF6139-BP	Affbiotech	1mg	EUR 234

BCL-3 Blocking Peptide
DF10317-BP	Affbiotech	1mg	EUR 234

BCLAF1 Peptide
8373P	ProSci	0.05 mg	EUR 197.7
Description: BCLAF1 Peptide

BCL2 (pT56) Blocking Peptide
20-abx061740	Abbexa	EUR 360.00 EUR 594.00	1 mg 5 mg

BCL2 (pS70) Blocking Peptide
20-abx061755	Abbexa	EUR 360.00 EUR 594.00	1 mg 5 mg

BCL2 (pS70) Blocking Peptide
20-abx062038	Abbexa	EUR 376.80 EUR 610.80	1 mg 5 mg

BCL2 (pT69) Blocking Peptide
20-abx062288	Abbexa	EUR 376.80 EUR 610.80	1 mg 5 mg

BCL2 (pS87) Blocking Peptide
20-abx161301	Abbexa	EUR 376.80 EUR 610.80	1 mg 5 mg

Bcl-B Peptide
3163P	ProSci	0.05 mg	EUR 197.7
Description: (IN) Bcl-B peptide

Bcl-G Peptide
3165P	ProSci	0.05 mg	EUR 197.7
Description: (NT) Bcl-G peptide

Bcl-xL Peptide
3341P	ProSci	0.05 mg	EUR 197.7
Description: (CT) Bcl-xL peptide

Bad / Bcl-2-like 8 Peptide
3343P	ProSci	0.05 mg	EUR 197.7
Description: (CT) Bad / Bcl-2-like 8 peptide

Bcl-rambo Peptide
3023P	ProSci	0.05 mg	EUR 197.7
Description: (IN) Bcl-rambo peptide

BCLW Blocking Peptide
20-abx062039	Abbexa	EUR 326.40 EUR 493.20	1 mg 5 mg

BclB Blocking Peptide
33R-10884	Fitzgerald	50 ug	EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BclB antibody, catalog no. 70R-12009

BCLW Blocking Peptide
DF3607-BP	Affbiotech	1mg	EUR 234

BCLX Blocking Peptide
20-abx161558	Abbexa	EUR 727.20 EUR 1713.60	1 mg 5 mg

bcl-2-related protein A1 Peptide
43-369P	ProSci	0.1 mg	EUR 405.6

BCLAF1 Blocking Peptide
20-abx063617	Abbexa	EUR 326.40 EUR 493.20	1 mg 5 mg

BCLAF1 Blocking Peptide
DF3828-BP	Affbiotech	1mg	EUR 234

Bcl xL Blocking Peptide
33R-10466	Fitzgerald	50 ug	EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl xL antibody, catalog no. 20R-1516

Bcl 6 Blocking Peptide
33R-10485	Fitzgerald	50 ug	EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl 6 antibody, catalog no. 20R-1556

Control/Blocking peptide Human BCL-2
BCL11-C	Alpha Diagnostics	100 ug	EUR 196.8

Control/Blocking peptide Mouse BCL-2
BCL21-C	Alpha Diagnostics	100 ug	EUR 196.8

Bcl-B Blocking Peptide
3695BP-50	Biovision	each	EUR 183.6

BCL-XL Blocking Peptide
AF6414-BP	Affbiotech	1mg	EUR 234

BCL-XL Blocking Peptide
AF6415-BP	Affbiotech	1mg	EUR 234

Bcl-xL Blocking Peptide
33R-10707	Fitzgerald	50 ug	EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl-xL antibody, catalog no. 70R-11750

Bcl-xL Blocking Peptide
3312BP-50	Biovision	each	EUR 183.6

BCLX (pS62) Blocking Peptide
20-abx161302	Abbexa	EUR 376.80 EUR 610.80	1 mg 5 mg

BCLX (pT47) Blocking Peptide
20-abx161557	Abbexa	EUR 1062.00 EUR 2548.80	1 mg 5 mg

Bcl-Rambo Blocking Peptide
3671BP-50	Biovision	each	EUR 183.6

TKD Peptide (Hsp70 Peptide) (Hsp70 Peptide)
SIH-118A	Stressmarq	1 mg	EUR 374.4
Description: The substance TKD Peptide (Hsp70 Peptide) is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution.

TKD Peptide (Hsp70 Peptide): FITC (Hsp70 Peptide)
SIH-119A	Stressmarq	1 mg	EUR 430.8
Description: The substance TKD Peptide (Hsp70 Peptide): FITC is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution.

TKD Peptide (Hsp70 Peptide)
abx076809-1mg	Abbexa	1 mg	EUR 594

Rat Peptide YY (PYY) Peptide
20-abx068453	Abbexa	EUR 744.00 EUR 326.40 EUR 2230.80 EUR 878.40 EUR 543.60	100 ug 10 ug 1 mg 200 ug 50 ug

Human Connecting Peptide (C-Peptide) Peptide
abx670072-05mg	Abbexa	0.5 mg	EUR 678

Human Peptide YY (PYY) Peptide
20-abx068451	Abbexa	EUR 693.60 EUR 309.60 EUR 2013.60 EUR 811.20 EUR 510.00	100 ug 10 ug 1 mg 200 ug 50 ug

Mouse Peptide YY (PYY) Peptide
20-abx068452	Abbexa	EUR 710.40 EUR 309.60 EUR 2131.20 EUR 844.80 EUR 526.80	100 ug 10 ug 1 mg 200 ug 50 ug

TKD Peptide (Hsp70 Peptide) (FITC)
abx076810-1mg	Abbexa	1 mg	EUR 678

Rat Connecting Peptide (C-Peptide) Peptide (OVA)
20-abx651058	Abbexa	EUR 510.00 EUR 276.00 EUR 1378.80 EUR 594.00 EUR 376.80	100 ug 10 ug 1 mg 200 ug 50 ug

BCL6 siRNA
20-abx908994	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

BCL6 siRNA
20-abx908995	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

Dog Peptide YY (PYY) Peptide (OVA)
20-abx651198	Abbexa	EUR 427.20 EUR 260.40 EUR 1178.40 EUR 526.80 EUR 343.20	100 ug 10 ug 1 mg 200 ug 50 ug

Pig Peptide YY (PYY) Peptide (OVA)
20-abx651200	Abbexa	EUR 427.20 EUR 260.40 EUR 1178.40 EUR 526.80 EUR 343.20	100 ug 10 ug 1 mg 200 ug 50 ug

Rat Peptide YY (PYY) Peptide (OVA)
20-abx651201	Abbexa	EUR 427.20 EUR 260.40 EUR 1178.40 EUR 526.80 EUR 343.20	100 ug 10 ug 1 mg 200 ug 50 ug

BCL6 antibody
10R-1574	Fitzgerald	100 ug	EUR 614.4
Description: Mouse monoclonal BCL6 antibody

BCL6 Antibody
25523-100ul	SAB	100ul	EUR 468

BCL6 Antibody
37150-100ul	SAB	100ul	EUR 302.4

Bcl6 Antibody
AF6672	Affbiotech	100ul	EUR 420

BCL6 antibody
70R-11805	Fitzgerald	100 ug	EUR 552
Description: Rabbit polyclonal BCL6 antibody

BCL6 Antibody
6985-002mg	ProSci	0.02 mg	EUR 206.18
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML).

BCL6 Antibody
6985-01mg	ProSci	0.1 mg	EUR 523.7
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML).

Bcl6 antibody
70R-34469	Fitzgerald	100 ug	EUR 392.4
Description: Rabbit polyclonal Bcl6 antibody

Bcl6 Antibody
ABD2903	Lifescience Market	100 ug	EUR 525.6

BCL6 Antibody
ABD7508	Lifescience Market	100 ug	EUR 525.6

BCL6 Antibody
1-CSB-PA005439	Cusabio	EUR 266.40 EUR 234.00	100ug 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

Bcl6 Antibody
DF2903	Affbiotech	200ul	EUR 420

BCL6 Antibody
1-CSB-PA171912	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

BCL6 Antibody
1-CSB-PA040220	Cusabio	EUR 266.40 EUR 234.00	100ug 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000

BCL6 Antibody
1-CSB-PA040221	Cusabio	EUR 266.40 EUR 234.00	100ug 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000

BCL6 Antibody
1-CSB-PA908823	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

BCL6 Antibody
F50351-0.08ML	NSJ Bioreagents	0.08 ml	EUR 140.25
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors.

BCL6 Antibody
F50351-0.4ML	NSJ Bioreagents	0.4 ml	EUR 322.15
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors.

BCL6 Antibody
F40298-0.08ML	NSJ Bioreagents	0.08 ml	EUR 140.25
Description: The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene.

BCL6 Antibody
F42687-0.08ML	NSJ Bioreagents	0.08 ml	EUR 140.25
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt]

BCL6 Antibody
F42687-0.4ML	NSJ Bioreagents	0.4 ml	EUR 322.15
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt]

Bcl6 Antibody
RQ4637	NSJ Bioreagents	100ug	EUR 356.15
Description: B-cell lymphoma 6 protein is a protein that in human is encoded by the BCL6 gene. Like BCL2, BCL3, BCL5, BCL7A, BCL9 and BCL10, it has clinical significance in lymphoma. The protein encoded by this gene is an evolutionarily conserved zinc finger transcription factor and contains an N-terminal POZ/BTB domain. This protein acts as a sequence-specific repressor of transcription and has been shown to modulate the STAT-dependent Interleukin 4 (IL-4) responses of B cells. This protein can interact with several corepressor complexes to inhibit transcription. This gene is found to be frequently translocated and hypermutated in diffuse large B cell lymphoma (DLBCL) and contributes to the pathogenesis of DLBCL. An exon 7 skipping splice variant encodes a shorter form of the protein which lacks the first two zinc fingers of the DNA binding domain.

Bcl6 Antibody
V3457-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3457-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3457SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3495-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3495-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3495SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3496-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3496-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3496SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3712-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3712-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3712SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3805-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3805-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V3805SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V7340-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V7340-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V7340IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V7340SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V7350-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody
V7350-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody
V7350IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody
V7350SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody
V2840-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V2840-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V2840IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V2840SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8063-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8063-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8063SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8064-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8064-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody
V8064SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Mouse Peptide YY (PYY) Peptide (OVA)
20-abx651199	Abbexa	EUR 427.20 EUR 260.40 EUR 1178.40 EUR 526.80 EUR 343.20	100 ug 10 ug 1 mg 200 ug 50 ug

Human Peptide YY (PYY) Peptide (OVA)
20-abx651848	Abbexa	EUR 693.60 EUR 309.60 EUR 2064.00 EUR 828.00 EUR 510.00	100 ug 10 ug 1 mg 200 ug 50 ug

Rat Galanin Like Peptide (GALP) Peptide
20-abx650475	Abbexa	EUR 777.60 EUR 326.40 EUR 2364.00 EUR 927.60 EUR 560.40	100 ug 10 ug 1 mg 200 ug 50 ug

Peptide 810
H-2586.0001	Bachem	1.0mg	EUR 529.2
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1]

Peptide 810
H-2586.0005	Bachem	5.0mg	EUR 2010
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1]

Peptide 401
HY-12537	MedChemExpress	500ug	EUR 523.2

Human Caspase peptide-17(Caspase peptide-17)
QY-E05408	Qayee Biotechnology	96T	EUR 433.2

Formyl Peptide Receptor-like 2 Peptide
43-293P	ProSci	0.1 mg	EUR 405.6

Dog Brain Natriuretic Peptide (BNP) Peptide
20-abx065598	Abbexa	EUR 1062.00 EUR 393.60 EUR 3400.80 EUR 1262.40 EUR 727.20	100 ug 10 ug 1 mg 200 ug 50 ug

Pig Brain Natriuretic Peptide (BNP) Peptide
20-abx065601	Abbexa	EUR 994.80 EUR 376.80 EUR 3199.20 EUR 1195.20 EUR 693.60	100 ug 10 ug 1 mg 200 ug 50 ug

Rat Brain Natriuretic Peptide (BNP) Peptide
20-abx652109	Abbexa	EUR 910.80 EUR 360.00 EUR 2865.60 EUR 1095.60 EUR 644.40	100 ug 10 ug 1 mg 200 ug 50 ug

Canine C Peptide(C Peptide) ELISA Kit
ECA0028	FN Test	96T	EUR 681.12
Description: Method of detection: Coated with Antigen, Competitive ELISA;Reacts with: Canine;Sensitivity: 0.469 ng/ml

Rat Atrial Natriuretic Peptide (ANP) Peptide
20-abx065483	Abbexa	EUR 693.60 EUR 309.60 EUR 2064.00 EUR 828.00 EUR 510.00	100 ug 10 ug 1 mg 200 ug 50 ug

Rat Atrial Natriuretic Peptide (ANP) Peptide
20-abx065484	Abbexa	EUR 777.60 EUR 326.40 EUR 2331.60 EUR 910.80 EUR 560.40	100 ug 10 ug 1 mg 200 ug 50 ug

Now it is clear that IAPP can also have a pathological role in AD, reducing cognitive function. IAPP harms blood-brain barriers, directly interacting and co-deposits with Aβ, promoting dementia associated with diabetes. IAPP can cause metabolic dysfunction in the brain, which leads to other diabetes advertisements. Thus, here we discuss the IAPP associations with diabetes, Aβ and dementia, in the context of what we specify “brain diabetes phenotype”. The hypothesis such approach helps establish a conceptual framework for IAPP-based drugs in the future against AD.